Member Info for Cheapsharesboy

Thanks Tom

Maybe they can't cost cut since

"stores now represent 76% of our revenue and online is 22%, with other, mainly gym memberships, outdoor living equipment and some wholesale revenue, at 2%"

Gyms only less than 2% of revenue means nothing to cut there! That's an astonishing figure though. I've spent money on these gyms - never in store,!

Why would you?

I'm in the minority I guess!

It's incredible that the gyms are completely packed yet in comparison to stores do not bring much in!

Very strange or is it that they don't have enough of gyms around?!?

Is JD sports doing any cost cutting?

I go to the gym and to me it appears overstaffed

I would imagine that they could easily cut?

Likely to rise after consolidation.

Dip below 8p this week - It's not going to take much to take this over 10p

It might be quite fast and you'll miss the boat. Adios Amigos!

Another clown talking about fund raise.

I'm gettting bored at these.

But will hold! It is a top pick right now with no urgent fund raises necessary.

Please read the NEWS!!!!

Well done to holders!

I have a question:

When is it likely that QBT actually mined a single bitcoin?

When is this gonna likely happen?

Has team17 implemented the use of Ai?

Not sure there is any mention of it in half year results!?

Sold mine today at 3.25 just 2 mins ago

Was bought yesterday at 2.6p

Best of luck to all real holders

I believe it worth 10p

But for it was just a trade

Oh wait!

What happened to the equity placement?

Did I miss it or something?

Come on losers!

How many eggs do you want on your face?

Nuff said

Is the spread always this insane?

Ig index saying 2.3 sell 2.8 buy

All you need to do is be patient and wait for a year.

These self proclaimed gurus like Peter pharma has never made a penny here or any other shares.

That's exactly why they brag here because they have no money nothing to do. So all they can do is talk about their illusionary profits

I don't hold the shares here

But I can say the nominal value 1p doesn't mean there be placing at 1p like Pete fatasist wants to say

Ignore the ignorant and buy if it's fundamentally good value. Best of luck

Thanks Mark

Looks like the general market mood is now the biggest influence not charts of this company.

Well at least until 23rd then we'll see if cmcx beats the market or sinks further. I'm optimistic that the undervaluation is too large to ignore in the 23rd.

Rationally I think it's targeting 50% retracement at around 218-219p. Please correct me if this figure is incorrect but it can't be far, rise from 89p to 349p gives 219p. So I think for traders, long probably set where stop losses sit below the 50% fib. So I would buy/go long at around 212/213p ISH.

Weakness in Sterling has definitely benefitted TCap as 60% of revenue is in US dollars but only 40% in expenses.

Should add a few million to the profit line, I'm not going to suggest the market is going to care much, however, this trend will likely persist and sterling is likely to weaken further, knowing the state this country is in. Should boost the profits; along with growth in currency and rates trading also persisting longer than expected. These "lower interest rates" seem like a distant pipe dream, unless if the Trump effect will be felt here as well.

Up 5 % yesterday all wiped out today

I think Cruddas needs to introduce an aggressive s

hare buyback to stop this sort of nonsense

I just wondered if Revolut needs CMC all together.

It would sort of make sense. I did a crypto trade there on Rev and I think you can trade stocks too ?

Maue sense if they buy CMC completely.

Would be peanuts for them eh

Did someone just wake up?

I can only imagine that the ifrs loss is going to be massive

That may not necessarily affect the dividend but on paper I recon MNG will be booking a huge loss as per IFRS standards.

Also remember that weak £ is making FAB really cheap for US buyers. Not to mention that it's 10x undervalued in its own right,!

Here

3.22pm: GSK (LON:GSK) cancer M&A

UK pharma giant GSK PLC (LSE:GSK, NYSE:GSK) is close to buying a US biotech, the FT is reporting.

It will pay $1 billion for startup IDRx, which was only founded in 2022, to boost its cancer drug business.

Backed by a raft of venture capital and private equity firms, the Massachusetts-based firm has been developing a treatment for gastrointestinal tumours.